Biotech and Pharmaceuticals Life Sciences

More

  • NEW YORK, Oct 27- Growing sales of expensive new cancer drugs and other newer medicines propelled top U.S. drugmakers Pfizer Inc, Merck& Co and Bristol-Myers Squibb Co to stronger-than-expected third-quarter profits. The results, announced on Tuesday, demonstrate that the "patent cliff" that had been hurting earnings as huge-selling drugs like Pfizer's...

  • *Losmapimod fails to show efficacy in first part of study. LONDON, Oct 27- An experimental heart drug from GlaxoSmithKline failed to work as hoped in the first part of a large clinical trial, the company said on Tuesday, dealing a blow to its pipeline of new medicines. Consensus forecasts currently point to Shingrix annual sales of $595 million by 2020, according to...

  • Oct 19- Drug developer Genocea Biosciences Inc said it was suspending the development of a vaccine for pneumonia-causing bacteria after it failed to significantly reduce infection in a mid-stage study. The company's shares fell 34 percent to $4.75 in premarket trading. The World Health Organization estimates that up to 1.6 million people, including...

  • Oct 19- Drug developer Genocea Biosciences Inc said it was suspending the development of a vaccine for pneumonia-causing bacteria after it failed to significantly reduce infection in a mid-stage study.

  • Oct 16- The U.S. Food and Drug Administration notified Shire Plc it will not approve its eye drug Lifitegrast, the company said on Friday, adding that the U.S. health regulator recommended the company conduct additional clinical studies. The news comes over a week before the FDA was supposed to make a decision on Lifitegrast on Oct 25. Shire said it received a...

  • Oct 16- Hong Kong- based drugmaker Hutchison China MediTech Ltd has filed for an initial public offering in the United States, according to a regulatory filing. In the corresponding period last year, the listing of 10 Chinese companies in the United States had raised over $3.5 billion, according to Thomson Reuters data. The company, which listed on the London Stock...

  • Oct 15- Bristol-Myers Squibb Co said on Thursday it agreed to exclusively license and collaborate with Five Prime Therapeutics Inc to develop and commercialize Five Prime's antibody program in the treatment of cancer. Five Prime will receive $350 million upfront and potential development and regulatory milestone payments, totaling $1.74 billion, for the...

  • *Dr Reddy's sees launching first biosimilar in US by 2018. MUMBAI, Oct 15- India, which has dominated the generic drugs industry for decades, is falling behind in the race to make copies of complex biotech drugs, which are expected to generate tens of billions of dollars in sales in the coming years. Just three Indian groups- Biocon Ltd, Dr Reddy's Laboratories Ltd and...

  • Oct 9- The U.S. Food and Drug Administration on Friday expanded its approval of Bristol-Myers Squibb Co's immunotherapy drug Opdivo for patients with an additional form of advanced lung cancer. While the expanded approval was widely expected based on clinical trial data, the FDA announcement came about three months ahead of the agency's mid-January action...

  • Johnson & Johnson starts Ebola vaccine trial Friday, 9 Oct 2015 | 8:14 AM ET
    People wearing protective clothing for the Ebola virus, in Freetown, Sierra Leone, September 28, 2014.

    Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.

  • Oct 9- Johnson& Johnson has begun a clinical trial of a two-shot Ebola vaccine in Sierra Leone, underlining its determination to push ahead with development, even as the epidemic fades out in West Africa. The new study will investigate the experimental product's safety and its ability to provoke an immune response to the disease, which the World Health...

  • Oct 9- Johnson& Johnson has begun a clinical trial of a two-shot Ebola vaccine in Sierra Leone, underlining its determination to push ahead with development, even as the epidemic fades out West Africa. The new study will investigate the experimental product's safety and its ability to provoke an immune response in the body to the disease, which the World Health...

  • Oct 5- Spark Therapeutics Inc's experimental gene therapy helped improve vision in patients with a type of inherited eye disorder in a late-stage study, bringing it a step closer to becoming the first gene therapy to win U.S. approval. While there is no currently approved treatments for IRDs, the results place Spark comfortably one step ahead of its...

  • Oct 5- Spark Therapeutics Inc said its experimental gene therapy helped improve vision in patients with a type of inherited eye disorder in a late-stage study, sending its shares up more than 50 percent in premarket trading. Spark, whose shares were trading at $69.51 before the opening bell, said it would file for marketing approval in the United States in 2016..

  • Oct 5- Drug developer Spark Therapeutics Inc said its experimental gene therapy helped improve vision in patients with a type of inherited eye disorder in a late-stage study. However, investor interest in the field has grown this year, with Bluebird Bio Inc, UniQure NV and Spark all staging successful Nasdaq debuts. Up to Friday's close, Spark's shares had risen...

  • Teva agreed in July to buy Allergan's generic drugs business for $40.5 billion in cash and stock, leaving Allergan to focus on paying down debt and potential "transformational" acquisitions. Allergan has always expanded its portfolio through acquisitions, the latest being a $2.1 billion offer to buy Kythera Biopharmaceuticals Inc in June.

  • ZURICH, Sept 27- Roche' s new immune-system boosting cancer drug has given positive results in tests on patients suffering from some lung and bladder cancers, according to data released on Sunday at the European Cancer Congress in Vienna that the company hopes will help it win quick regulatory approval. Roche, the largest maker of cancer drugs, is banking on...

  • Why dried toad still beats vitamin C in China Tuesday, 22 Sep 2015 | 10:48 PM ET
    Products are for sale at a traditional Chinese medicine market in Bozhou, Anhui Province, China.

    China's much-hyped market for vitamins and supplements is facing a steep challenge from traditional remedies from ginseng to deer antler.

  • Mapp Biopharma's Ebola drug gets FDA fast track status Thursday, 17 Sep 2015 | 11:18 AM ET

    Sept 17- Mapp Biopharmaceutical Inc said on Thursday that the U.S. Food and Drug Administration granted fast track status to its Ebola drug ZMapp. The Ebola epidemic is the largest in history, affecting multiple countries in West Africa, according to the Centers for Disease Control and Prevention. Cases were reported in Liberia, Nigeria, Mali, Senegal, and has...

  • LONDON, Sept 15- The biotechnology sector is in a "bubble", pushing prices for medium-sized companies with experimental drugs in late-stage development out of reach, the chief executive of drugmaker Roche said on Tuesday. "I think this bubble will burst at some point," Severin Schwan told Reuters in an interview during a visit to London. Roche would continue to look...